An Observational Study Comparing the Risk of Acute Pancreatitis (AP) among New Users of Canagliflozin Versus Six Classes of Other Antihyperglycemic Agents (AHAs)
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Canagliflozin (Primary) ; Acarbose; Bromocriptine; Dipeptidyl peptidase 4 inhibitors; Glucagon-like peptide-1 receptor agonists; Insulin; Miglitol; Nateglinide; Repaglinide; Sulfonylureas; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
Most Recent Events
- 16 Jul 2019 New trial record
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.